Betulinic acid "buh-TOO-li-nik acid" is a natural compound with antiretroviral, anti malarial, anti-inflammatory and anticancer properties. It is found in the bark of several plants, such as white birch, ber tree and rosemary, and has a complex mode of action against tumor cells.
-Betulinic acid is a naturally occurring pentacyclic triterpenoid
-vitro concentrations range from 1–100 µM, in vivo studies in rodents have generally used doses from 10–100 mg/kg
Precursor: Betulin, via oxidation at C-28
Lipophilicity: High (poor aqueous solubility)
Betulinic acid — Betulinic acid is a naturally occurring lupane-type pentacyclic triterpenoid with broad experimental anticancer activity, especially against melanoma, neuroectodermal, glioma, breast, colorectal, and other solid-tumor models. It is a natural-product small molecule, usually abbreviated BA or BetA, and is found in several plants, classically birch bark, with semi-synthesis commonly starting from betulin. A distinguishing feature is preferential induction of tumor-cell death through direct mitochondrial injury with relative sparing of many non-neoplastic cells in preclinical systems. Its main translational limitation is very poor aqueous solubility with correspondingly weak oral/systemic developability unless formulation or derivatization is used.
Primary mechanisms (ranked):
- Direct mitochondrial membrane permeabilization with intrinsic apoptosis activation
- Mitochondrial ROS increase with collapse of mitochondrial membrane potential and cytochrome c release
- ER-stress and unfolded-protein-response activation, including GRP78-linked stress signaling
- Suppression of NF-κB and other pro-survival transcriptional programs, including Sp-family signaling in some models
- Cell-cycle arrest with reduced cyclin/CDK signaling
- Anti-migratory and anti-invasive effects via EMT, FAK, ROCK1, MMP, and cytoskeletal remodeling pathways
- Secondary metabolic suppression of aerobic glycolysis and hypoxia-response signaling in susceptible models
- Adjunct sensitization to chemo- or radiotherapy in selected preclinical settings
Bioavailability / PK relevance: Betulinic acid is highly lipophilic and poorly water-soluble, which strongly limits oral absorption and systemic exposure. PK behavior is formulation-dependent, and much of the translational literature focuses on nanoparticles, liposomes, micelles, conjugates, or topical delivery rather than conventional oral dosing.
In-vitro vs systemic exposure relevance: Many in-vitro anticancer studies use low-to-mid micromolar concentrations, which are often difficult to reproduce reliably in vivo with unformulated parent betulinic acid. Accordingly, mechanistic findings are useful biologically, but direct concentration matching to standard oral/systemic use is often poor unless enhanced-delivery systems are used.
Clinical evidence status: Strong preclinical and formulation-development literature; very limited human oncology evidence. Cancer-facing clinical development appears to remain early-phase/topical, with orphan designation for topical metastatic melanoma but no FDA approval for that indication. Betulinic acid itself is not an established approved anticancer drug.
-half-life reports vary 3-5 hrs?.
Reported half-life varies by formulation and species; several studies report multi-hour systemic persistence.
BioAv -hydrophobic molecule with relatively poor water solubility.
Main Cancer action
-Direct mitochondrial targeting in cancer cells
-Minimal effect on normal cells
Key pathways
-Mitochondrial membrane permeabilization
-ROS-mediated apoptosis
-Caspase-independent death
Chemo relevance: Generally compatible, Not a redox buffer
Pathways:
- often induce
ROS production
- ROS↑ related:
MMP↓(ΔΨm),
ER Stress↑,
UPR↑,
GRP78↑,
Ca+2↑,
Cyt‑c↑,
Caspases↑,
DNA damage↑,
cl-PARP↑,
HSP↓
- Lowers AntiOxidant defense in Cancer Cells(Often associated with reduced redox buffering capacity in tumor cells (e.g., GSH depletion); NRF2 direction model-dependent.):
NRF2↓,
SOD↓,
GSH↓
- May Raise
AntiOxidant
defense in Normal Cells:
NRF2↑,
SOD↑,
GSH↑,
Catalase↑
Reports suggest relative sparing of normal cells and preservation of antioxidant capacity in some models
- lowers
Inflammation :
NF-kB↓(typ),
COX2↓,
p38↓
(context-dependent; often stress-activated), Pro-Inflammatory Cytokines :
IL-1β↓,
TNF-α↓,
IL-6↓,
IL-8↓
- inhibit Growth/Metastases :
,
MMPs↓,
MMP2↓,
MMP9↓,
TIMP2,
IGF-1↓,
VEGF↓,
ROCK1↓,
FAK↓,
NF-κB↓,
TGF-β↓,
α-SMA↓,
ERK↓
- reactivate genes thereby inhibiting cancer cell growth :
P53↑,
HSP↓(model-dependent),
Sp proteins↓,
- cause Cell cycle arrest :
TumCCA↑,
cyclin D1↓,
CDK2↓,
CDK4↓,
- inhibits Migration/Invasion :
TumCMig↓,
TumCI↓,
FAK↓,
ERK↓,
EMT↓,
TOP1↓,
- inhibits
glycolysis
(secondary to mitochondrial stress)
ATP depletion :
HIF-1α↓,
PKM2↓,
cMyc↓,
GLUT1↓,
LDH↓,
LDHA↓,
HK2↓,
PFKs↓,
PDKs↓,
HK2↓,
ECAR↓,
GRP78↑(ER stress),
GlucoseCon↓
- inhibits
angiogenesis↓ :
VEGF↓,
HIF-1α↓,
EGFR↓,
- inhibits Cancer Stem Cells in some studies :
CSC↓,
GLi1↓,
β-catenin↓,
OCT4↓,
- Others: PI3K↓(typ),
AKT↓(typ),
JAK↓,
STAT↓,
β-catenin↓,
AMPK↓(AMPK is often activated during metabolic stress),
ERK↓,
JNK,
- Synergies:
chemo-sensitization,
chemoProtective,
RadioSensitizer,
Others(review target notes),
Neuroprotective,
Cognitive,
Renoprotection,
Hepatoprotective,
CardioProtective,
- Selectivity:
Cancer Cells vs Normal Cells
Mechanistic profile
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Mitochondrial permeabilization |
↑ MOMP, ↓ ΔΨm, ↑ cytochrome c release, ↑ apoptosis |
↔ / milder effect |
P-R |
Core tumor-selective death trigger |
Best-supported central mechanism; helps explain activity in apoptosis-competent but therapy-resistant tumors. |
| 2 |
Mitochondrial ROS increase |
↑ ROS |
↔ / possible antioxidant sparing (context-dependent) |
P-R |
Amplifies mitochondrial stress and death signaling |
ROS appears mechanistically relevant in many tumor models, but not every study makes it the dominant initiating event. |
| 3 |
Caspase axis and caspase-independent death |
↑ caspase-9, ↑ caspase-3, ↑ PARP cleavage; caspase-independent death also reported |
↔ |
R-G |
Executes apoptosis after mitochondrial injury |
BA can still kill some tumor cells when classical caspase execution is partly blocked, indicating non-canonical death contribution. |
| 4 |
ER stress / UPR / GRP78 |
↑ ER stress, ↑ UPR, ↑ GRP78 stress signaling |
↔ |
R-G |
Links proteostatic stress to apoptosis and metastasis suppression |
Especially relevant in breast and gastric cancer models; may also connect to metabolic suppression and chemosensitization. |
| 5 |
NF-κB survival signaling |
↓ NF-κB |
↔ / ↓ inflammatory tone |
R-G |
Reduces survival, inflammatory, and resistance programs |
Common downstream convergence node across several tumor types. |
| 6 |
Cell-cycle machinery |
↓ cyclin D1, ↓ CDK2, ↓ CDK4, ↑ cell-cycle arrest |
↔ |
G |
Slows proliferation |
Usually supportive rather than primary; often follows stress and survival-pathway disruption. |
| 7 |
EMT / invasion / matrix remodeling |
↓ EMT, ↓ FAK, ↓ ROCK1, ↓ MMP2, ↓ MMP9, ↓ migration, ↓ invasion |
↔ |
G |
Antimetastatic effect |
Consistent with reduced motility and invasive phenotype in multiple solid-tumor models. |
| 8 |
Glycolysis |
↓ glucose uptake, ↓ lactate, ↓ ECAR, ↓ HK2, ↓ PKM2, ↓ LDHA |
↔ |
G |
Secondary metabolic suppression |
Not the universal initiating mechanism; appears important in selected breast-cancer and GRP78-linked systems. |
| 9 |
HIF-1α hypoxia axis |
↓ HIF-1α, ↓ VEGF, ↓ GLUT1, ↓ PDK1 |
↔ |
G |
Reduces hypoxic adaptation and angiogenic drive |
Relevant in hypoxic tumor biology and helps explain antiangiogenic/metabolic effects in some models. |
| 10 |
NRF2 / antioxidant buffering |
↓ NRF2 or ↓ redox buffering (model-dependent) |
↔ / possible preservation of antioxidant tone (context-dependent) |
R-G |
May widen tumor redox vulnerability |
Direction is not uniform across all models; safer to treat this as contextual rather than universally core. |
| 11 |
Ca²⁺ stress |
↑ Ca²⁺ (context-dependent) |
↔ |
P-R |
Supports organelle stress and apoptotic signaling |
Usually part of the broader mitochondrial/ER stress network rather than a stand-alone primary target. |
| 12 |
Radiosensitization or Chemosensitization |
↑ sensitivity to radiation or selected drugs |
Unclear |
G |
Adjunct leverage |
Preclinical evidence supports additive or sensitizing effects with irradiation and with some chemotherapy settings, but this is not yet clinically established. |
| 13 |
Clinical Translation Constraint |
Poor solubility and limited systemic exposure constrain reproducibility |
Same formulation constraint |
G |
Delivery bottleneck |
Main barrier is not lack of mechanistic richness but drug-like exposure; translation currently depends heavily on formulation, derivatization, or topical/local use. |
Time-Scale Flag (TSF): P / R / G
- P: 0–30 min (primary/physical-chemical effects; rapid kinase/redox signaling)
- R: 30 min–3 hr (acute redox and stress-response activation)
- G: >3 hr (gene-regulatory adaptation and phenotypic outcomes)
|